胸腺肽联合化疗治疗非小细胞肺癌的疗效及对免疫功能的影响

目的探讨胸腺肽联合化疗治疗非小细胞肺癌的疗效及对免疫功能的影响。方法选取非小细胞肺癌患者200例,随机分成2组。2组患者化疗均采用基于顺铂的联合治疗方案,分别为长春瑞滨加顺铂(NP)、紫杉醇加顺铂(DP)方案和吉西他滨加顺铂(GP)方案。观察组患者在此基础上采用胸腺肽治疗。分别在化疗前、化疗后7 d以及化疗后28 d观察2组患者的T淋巴细胞亚群和NK细胞的变化,观察化疗过程中骨髓抑制、胃肠道反应等毒性反应。结果在化疗后7、28 d后,2组患者的T淋巴细胞亚群和NK细胞水平有显著差异(P0.05)。观察组患者骨髓抑制的发生率为29%,显著低于对照组的53%(P0.05)。观察组患者胃肠道反应的发生率为63%,显著低于对照组的98%(P0.05)。结论化疗联合胸腺肽可以显著提升非小细胞肺癌患者的免疫能力,减少抗癌药物毒性反应。

Efficacy of thymosin combined with chemotherapy in treatment of patients with non-small cell lung cancer and its influence on immune function

Objective To explore the efficacy of thymosin combined with chemotherapy in treatment of patients with non-small cell lung cancer (NSCLC) and its influence on immune function.Methods A total of 200 patients with NSCLC were selected and randomly divided into observation group and control group.All patients were treated with combined treatment,including vinorelbine plus cisplatin (NP),paclitaxel plus cisplatin (DP) and gemcitabine plus cisplatin (GP).On this basis,patients in observation group were treated with thymosin.Changes of T lymphocyte subsets and NK cells were compared before treatment and 7,28 days after chemotherapy between two groups,and the toxic reactions such as bone marrow depression and gastrointestinal reaction were observed.Results Seven and twenty-eight days after chemotherapy,there were significant differences of T lymphocyte subsets and NK cells between two groups (P ＜ 0.05).The incidence rate of myelosuppression in the observation group was 29％,which was significantly lower than 53％ in the control group (P ＜ 0.05).The incidence rate of gastrointestinal reaction in the observation group was 63％,which was significantly lower than 98％ in the control group (P ＜ O.05).Conclusion Chemotherapy combined with thymosin can significantly improve immunity ability of patients with non-small cell lung cancer,and reduce the toxicity of anti-cancer drugs.